Carregant...
CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies
As the incidence of cutaneous malignancies continues to rise and their treatment with immunotherapy expands, dermatologists and their patients are more likely to encounter these agents. While blockade of immune checkpoint target proteins (CTLA-4, PD-1, PD-L1) generates an antitumor response in a sub...
Guardat en:
| Publicat a: | J Am Acad Dermatol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7572574/ https://ncbi.nlm.nih.gov/pubmed/32461079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaad.2020.03.131 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|